Arcus Biosciences (NYSE:RCUS) Sets New 52-Week Low - Time to Sell?

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $13.51 and last traded at $13.65, with a volume of 227874 shares changing hands. The stock had previously closed at $14.20.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Arcus Biosciences in a report on Thursday, November 7th. Barclays raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Friday, October 25th. HC Wainwright reiterated a "neutral" rating and set a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Wells Fargo & Company started coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $29.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $34.00.

Arcus Biosciences Stock Down 1.5 %

The firm's 50 day moving average price is $15.77 and its two-hundred day moving average price is $15.96. The firm has a market capitalization of $1.28 billion, a PE ratio of -4.44 and a beta of 0.87. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $48.00 million during the quarter, compared to analysts' expectations of $38.95 million. During the same period in the prior year, the company posted ($0.94) EPS. The firm's revenue for the quarter was up 50.0% on a year-over-year basis. As a group, research analysts forecast that Arcus Biosciences, Inc. will post -3.2 EPS for the current fiscal year.

Insider Buying and Selling at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the company's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. This represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.30% of the stock is owned by insiders.

Institutional Trading of Arcus Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC raised its holdings in shares of Arcus Biosciences by 6.9% during the third quarter. FMR LLC now owns 4,467,557 shares of the company's stock worth $68,309,000 after purchasing an additional 286,766 shares during the period. Point72 Asset Management L.P. grew its position in shares of Arcus Biosciences by 32.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company's stock valued at $37,263,000 after buying an additional 603,222 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in Arcus Biosciences by 146.9% during the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock worth $15,684,000 after acquiring an additional 610,219 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Arcus Biosciences by 25.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company's stock worth $14,236,000 after acquiring an additional 186,750 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock valued at $8,669,000 after acquiring an additional 59,536 shares during the period. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.